STOK

SEC source: 0001209191-21-054552 · doc4.xml · nonDerivative · entry 1

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-049793 · doc4.xml · derivative · entry 3

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,422

Underlying: Common Stock · 5,700 shares

Expires 2028-12-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-21-049793 · doc4.xml · nonDerivative · entry 2

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.68 to $29.32 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-049793 · doc4.xml · nonDerivative · entry 1

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-046830 · doc4.xml · nonDerivative · entry 2

Ticho Barry · CIK 0001780088 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,895

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.21 to $34.17 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-046830 · doc4.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,195

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.19 to $33.16 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes 430 shares of Common Stock acquired under the issuer's employee stock purchase plan on June 30, 2021.

SEC source: 0001209191-21-045097 · doc4.xml · derivative · entry 3

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,122

Underlying: Common Stock · 5,700 shares

Expires 2028-12-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-21-045097 · doc4.xml · nonDerivative · entry 2

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.03 to $33.80 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-045097 · doc4.xml · nonDerivative · entry 1

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-21-006113 · form4.xml · nonDerivative · entry 1

ATP Life Science Ventures, L.P. · CIK 0001593440 · 10% owner

ATP III GP, Ltd. · CIK 0001593453 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.).

F1 · price: The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.).

F2 · ownership.direct: The shares were directly held by ATP. ATP III GP, Ltd. ("ATP GP") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP and Dr. Harrison disclaim beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-21-043332 · doc4.xml · derivative · entry 1

Krainer Adrian R. · CIK 0001780081 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,650

Underlying: Common Stock · 11,650 shares

Expires 2031-06-07

F1 · derivative.exercise_date: The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.

SEC source: 0001209191-21-043334 · doc4.xml · derivative · entry 1

LEVIN ARTHUR A · CIK 0001181556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,650

Underlying: Common Stock · 11,650 shares

Expires 2031-06-07

F1 · derivative.exercise_date: The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.

SEC source: 0001209191-21-043340 · doc4.xml · derivative · entry 1

TZIANABOS ARTHUR · CIK 0001586226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,650

Underlying: Common Stock · 11,650 shares

Expires 2031-06-07

F1 · derivative.exercise_date: The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.

SEC source: 0001209191-21-043338 · doc4.xml · derivative · entry 1

Smith Julie · CIK 0001557928 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,650

Underlying: Common Stock · 11,650 shares

Expires 2031-06-07

F1 · derivative.exercise_date: The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.

SEC source: 0001209191-21-043335 · doc4.xml · derivative · entry 1

Menzel Garry E · CIK 0001556064 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,650

Underlying: Common Stock · 11,650 shares

Expires 2031-06-07

F1 · derivative.exercise_date: The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.

SEC source: 0001209191-21-043330 · doc4.xml · derivative · entry 1

Harrison Seth Loring · CIK 0001404955 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,650

Underlying: Common Stock · 11,650 shares

Expires 2031-06-07

F1 · derivative.exercise_date: The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.

F2 · ownership.direct: Under the reporting person's arrangement with Apple Tree Life Sciences, Inc. (the "Manager"), the reporting person holds the option for the benefit of Apple Tree Partners IV, L.P. (the "Fund"). The reporting person is obligated to turn over to the Manager any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Manager. The reporting person therefore disclaims beneficial ownership of the option and underlying common stock.

SEC source: 0001209191-21-043329 · doc4.xml · derivative · entry 1

Burstein Jennifer · CIK 0001640069 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,650

Underlying: Common Stock · 11,650 shares

Expires 2031-06-07

F1 · derivative.exercise_date: The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.

SEC source: 0001209191-21-037839 · doc4.xml · derivative · entry 3

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,822

Underlying: Common Stock · 575 shares

Expires 2028-12-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-21-037839 · doc4.xml · nonDerivative · entry 2

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.17 to $39.70 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-037839 · doc4.xml · nonDerivative · entry 1

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 575

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-017876 · doc4.xml · derivative · entry 2

Ticho Barry · CIK 0001780088 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,600

Underlying: Common Stock · 65,600 shares

Expires 2031-03-01

F2 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-21-017878 · doc4.xml · derivative · entry 1

Tulipano Stephen J · CIK 0001360548 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,600

Underlying: Common Stock · 65,600 shares

Expires 2031-03-01

F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-21-017874 · doc4.xml · derivative · entry 1

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,600

Underlying: Common Stock · 65,600 shares

Expires 2031-03-01

F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-21-017869 · doc4.xml · derivative · entry 8

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,874

Underlying: Common Stock · 5,195 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-21-017869 · doc4.xml · derivative · entry 7

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,800

Underlying: Common Stock · 40,800 shares

Expires 2031-03-01

F5 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-21-017869 · doc4.xml · nonDerivative · entry 5

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,351

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.13 to $63.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-017869 · doc4.xml · nonDerivative · entry 4

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,251

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.93 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-017869 · doc4.xml · nonDerivative · entry 3

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,546

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-017865 · doc4.xml · derivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,800

Underlying: Common Stock · 200,800 shares

Expires 2031-03-01

F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-21-017020 · doc4.xml · derivative · entry 9

LEVIN ARTHUR A · CIK 0001181556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,764

Underlying: Common Stock · 7,882 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option vested as to 1/48th of the total shares on February 28, 2018, and then 1/48th of the total shares vest at the end of each month thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-21-017020 · doc4.xml · derivative · entry 8

LEVIN ARTHUR A · CIK 0001181556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,842 shares

Expires 2027-02-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option is 100% vested and exercisable.

SEC source: 0001209191-21-017020 · doc4.xml · derivative · entry 7

LEVIN ARTHUR A · CIK 0001181556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,776 shares

Expires 2026-02-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option is 100% vested and exercisable.

SEC source: 0001209191-21-017020 · doc4.xml · nonDerivative · entry 5

LEVIN ARTHUR A · CIK 0001181556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.90 to $61.80 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-017020 · doc4.xml · nonDerivative · entry 4

LEVIN ARTHUR A · CIK 0001181556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,957

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.89 to $60.88 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-017020 · doc4.xml · nonDerivative · entry 3

LEVIN ARTHUR A · CIK 0001181556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-017020 · doc4.xml · nonDerivative · entry 2

LEVIN ARTHUR A · CIK 0001181556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,618

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-017020 · doc4.xml · nonDerivative · entry 1

LEVIN ARTHUR A · CIK 0001181556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,776

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-013897 · doc4.xml · derivative · entry 8

Tulipano Stephen J · CIK 0001360548 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,997

Underlying: Common Stock · 5,000 shares

Expires 2029-03-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vested as to 1/4th of the total shares on March 15, 2020, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-21-013897 · doc4.xml · nonDerivative · entry 6

Tulipano Stephen J · CIK 0001360548 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 602

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-21-013897 · doc4.xml · nonDerivative · entry 5

Tulipano Stephen J · CIK 0001360548 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,602

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-013897 · doc4.xml · derivative · entry 7

Tulipano Stephen J · CIK 0001360548 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 184,997

Underlying: Common Stock · 25,000 shares

Expires 2029-03-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vested as to 1/4th of the total shares on March 15, 2020, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-21-013897 · doc4.xml · nonDerivative · entry 4

Tulipano Stephen J · CIK 0001360548 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 602

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-21-013897 · doc4.xml · nonDerivative · entry 3

Tulipano Stephen J · CIK 0001360548 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 704

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.96 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-013897 · doc4.xml · nonDerivative · entry 2

Tulipano Stephen J · CIK 0001360548 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,400

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-013897 · doc4.xml · nonDerivative · entry 1

Tulipano Stephen J · CIK 0001360548 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,602

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-013320 · doc4.xml · derivative · entry 3

TZIANABOS ARTHUR · CIK 0001586226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,447

Underlying: Common Stock · 10,000 shares

Expires 2028-12-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vested as to 1/48th of the total shares on October 4, 2018 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-21-013320 · doc4.xml · nonDerivative · entry 2

TZIANABOS ARTHUR · CIK 0001586226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-21-013320 · doc4.xml · nonDerivative · entry 1

TZIANABOS ARTHUR · CIK 0001586226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-002246 · doc4.xml · nonDerivative · entry 6

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-21-002246 · doc4.xml · derivative · entry 7

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,397

Underlying: Common Stock · 5,700 shares

Expires 2018-12-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.